Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In...

Area of Science:

• Oncology
• Genomics
• Clinical Management

Background:

• Genomic testing is increasingly vital for prostate cancer (PCa) management and hereditary cancer assessment.
• Challenges persist in optimal implementation and end-user confidence regarding genomic testing.

Purpose of the Study:

• To assess the utility and understanding of genomic testing among PCa healthcare providers, researchers, and stakeholders.
• To identify barriers and facilitators impacting the clinical integration of genomic testing in PCa care.

Main Methods:

• The Decision-making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) survey was used.
• The online survey collected data from 122 participants on confidence, testing processes, decision-making, and barriers.
• Descriptive statistics were employed to summarize survey responses.

Main Results:

• High confidence was reported for ordering genomic tests, but lower confidence existed for interpreting results, particularly from circulating tumor DNA.
• Barriers included difficulty obtaining tissue (71%) and cost (35%).
• Limited ability to obtain recommended treatments (33%) and a lack of education (55%) impeded clinical translation.

Conclusions:

• The DECIDE survey highlights provider confidence gaps in interpreting genomic test results and practical barriers to testing.
• Enhanced education and improved reporting are crucial for better implementation of genomic testing in prostate cancer care.